These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 9790452

  • 1. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites.
    Sàbat M, Guarner C, Soriano G, Bulbena O, Novella MT, Ortiz J, Ricart E, Villanueva C, Rosello J, Rodríguez J, Balanzó J.
    Dig Dis Sci; 1998 Oct; 43(10):2184-9. PubMed ID: 9790452
    [Abstract] [Full Text] [Related]

  • 2. The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
    Kalambokis G, Economou M, Kosta P, Papadimitriou K, Tsianos EV.
    J Clin Gastroenterol; 2006 Apr; 40(4):342-6. PubMed ID: 16633107
    [Abstract] [Full Text] [Related]

  • 3. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
    Kalambokis G, Economou M, Fotopoulos A, Al Bokharhii J, Pappas C, Katsaraki A, Tsianos EV.
    Am J Gastroenterol; 2005 Apr; 100(4):879-85. PubMed ID: 15784036
    [Abstract] [Full Text] [Related]

  • 4. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, Finucci GF, Casiglia E, Sticca A, De Toni R, Pavan L, Gatta A.
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [Abstract] [Full Text] [Related]

  • 5. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites.
    Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Katsaraki A, Tsianos EV.
    Nephrol Dial Transplant; 2005 Aug; 20(8):1623-9. PubMed ID: 15886218
    [Abstract] [Full Text] [Related]

  • 6. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
    Singh V, Dhungana SP, Singh B, Vijayverghia R, Nain CK, Sharma N, Bhalla A, Gupta PK.
    J Hepatol; 2012 Feb; 56(2):348-54. PubMed ID: 21749847
    [Abstract] [Full Text] [Related]

  • 7. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A.
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [Abstract] [Full Text] [Related]

  • 8. Effects of captopril on renal functions, renal and portal hemodynamics in patients with cirrhosis.
    Tsai YT, Lin HC, Lee FY, Hou MC, Wang SS, Lee SD.
    Proc Natl Sci Counc Repub China B; 1996 Apr; 20(2):44-50. PubMed ID: 8931343
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Octreotide in the treatment of refractory ascites of cirrhosis.
    Kalambokis G, Fotopoulos A, Economou M, Tsianos EV.
    Scand J Gastroenterol; 2006 Jan; 41(1):118-21. PubMed ID: 16373285
    [Abstract] [Full Text] [Related]

  • 12. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension.
    Escorsell A, Bandi JC, Andreu V, Moitinho E, García-Pagán JC, Bosch J, Rodés J.
    Gastroenterology; 2001 Jan; 120(1):161-9. PubMed ID: 11208725
    [Abstract] [Full Text] [Related]

  • 13. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F, Pantea L, Sniderman K.
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study.
    Ludwig D, Schädel S, Brüning A, Schiefer B, Stange EF.
    Dig Dis Sci; 2000 May; 45(5):1019-27. PubMed ID: 10795771
    [Abstract] [Full Text] [Related]

  • 16. Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites.
    Luca A, Feu F, García-Pagán JC, Jiménez W, Arroyo V, Bosch J, Rodés J.
    Hepatology; 1994 Jul; 20(1 Pt 1):30-3. PubMed ID: 8020901
    [Abstract] [Full Text] [Related]

  • 17. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.
    Saló J, Ginès A, Quer JC, Fernández-Esparrach G, Guevara M, Ginès P, Bataller R, Planas R, Jiménez W, Arroyo V, Rodés J.
    J Hepatol; 1996 Dec; 25(6):916-23. PubMed ID: 9007721
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.